Biomerica up on planned launch of bowel disorder test this year

Biomerica

30/08/2022 16:40

** Biomerica Inc's shares  BMRA.O  rise 7.4% to $3.6 
    ** Co says it plans to launch its IBS test before calendar
year end  urn:newsml:reuters.com:*:nGNX5fmb78
    ** Test is developed to check a patient's above normal
immunoreactivity to specific foods that cause irritable bowel
syndrome
    ** Co will currently offer the test, which has not yet
received FDA authorization, as a laboratory developed test 
    ** Co has hired Robert Carlson to serve as chief commercial
officer in preparation for the launch
    ** Including session gains, stock down ~7% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))